ATE492289T1 - Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln - Google Patents

Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln

Info

Publication number
ATE492289T1
ATE492289T1 AT05075889T AT05075889T ATE492289T1 AT E492289 T1 ATE492289 T1 AT E492289T1 AT 05075889 T AT05075889 T AT 05075889T AT 05075889 T AT05075889 T AT 05075889T AT E492289 T1 ATE492289 T1 AT E492289T1
Authority
AT
Austria
Prior art keywords
virus
hbv
particles
preparation
capsid protein
Prior art date
Application number
AT05075889T
Other languages
German (de)
English (en)
Inventor
Robert C Rose
William Bonnez
Richard C Reichman
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE492289(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE492289T1 publication Critical patent/ATE492289T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT05075889T 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln ATE492289T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07

Publications (1)

Publication Number Publication Date
ATE492289T1 true ATE492289T1 (de) 2011-01-15

Family

ID=26703787

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94912186T ATE296111T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
AT05075369T ATE494005T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen
AT05075889T ATE492289T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT94912186T ATE296111T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
AT05075369T ATE494005T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen

Country Status (13)

Country Link
EP (3) EP1588713B1 (enExample)
JP (4) JPH08507685A (enExample)
AT (3) ATE296111T1 (enExample)
AU (3) AU688759C (enExample)
CA (1) CA2157932C (enExample)
DE (9) DE69434383T2 (enExample)
DK (2) DK1618888T3 (enExample)
ES (3) ES2242955T4 (enExample)
FR (1) FR11C0022I2 (enExample)
LU (3) LU91313I2 (enExample)
NL (3) NL300265I2 (enExample)
PT (2) PT1618888E (enExample)
WO (1) WO1994020137A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000023I1 (de) 1991-07-19 2007-08-09 Univ Queensland St Lucia Impfsstoff gegen Humanes Papillomavirus (typ 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
DE59511047D1 (de) * 1994-10-07 2006-06-14 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
EP0863982B1 (en) * 1995-11-15 2004-01-21 Merck & Co., Inc. Synthetic hpv11 virus-like particles
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
ATE256734T1 (de) * 1996-10-04 2004-01-15 Merck & Co Inc Synthetische hpv16 virus-ähnliche partikel
CA2274474C (en) * 1996-12-09 2008-07-22 Steven Ludmerer Synthetic hpv16 virus-like particles
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
ATE490346T1 (de) * 2000-09-18 2010-12-15 Medimmune Llc In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1425423B1 (en) 2001-08-13 2010-06-23 University of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (en) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
DK2910566T5 (en) 2007-05-29 2016-11-07 Univ Xiamen Truncated L1 protein of human papillomavirus 11
US8748127B2 (en) 2007-05-29 2014-06-10 Xiamen University Truncated L1 protein of human papillomavirus type 6
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
ES2565846T3 (es) 2008-05-26 2016-04-07 Cadila Healthcare Limited Vacuna combinada contra el sarampión-papiloma humano
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2643498T3 (es) 2010-04-08 2017-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ensayo de células presentadoras de antígenos de linfocitos B
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
BR112014023092A8 (pt) 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DE122007000023I1 (de) 1991-07-19 2007-08-09 Univ Queensland St Lucia Impfsstoff gegen Humanes Papillomavirus (typ 18)

Also Published As

Publication number Publication date
NL300265I2 (nl) 2008-05-01
LU91392I2 (fr) 2008-02-14
DE05075889T1 (de) 2006-10-05
CA2157932A1 (en) 1994-09-15
EP0688227A1 (en) 1995-12-27
JP4486075B2 (ja) 2010-06-23
ES2263406T1 (es) 2006-12-16
AU2007201006A1 (en) 2007-03-29
AU2007201005B2 (en) 2010-06-10
ATE296111T1 (de) 2005-06-15
DE05075369T1 (de) 2006-11-16
LU91391I2 (fr) 2008-02-14
FR11C0022I2 (fr) 2012-08-03
JP2010148514A (ja) 2010-07-08
DE122007000090I1 (de) 2008-03-27
DE69435332D1 (de) 2011-02-17
AU6443694A (en) 1994-09-26
AU688759B2 (en) 1998-03-19
EP0688227B1 (en) 2005-05-25
DE122007000014I1 (de) 2007-05-24
EP1588713A1 (en) 2005-10-26
ATE494005T1 (de) 2011-01-15
EP1618888B1 (en) 2011-01-05
AU688759C (en) 2006-12-21
AU2007201005A1 (en) 2007-03-29
NL300265I1 (nl) 2007-05-01
CA2157932C (en) 2011-10-11
HK1082196A1 (en) 2006-06-02
NL300310I1 (nl) 2008-02-01
NL300309I2 (nl) 2008-03-03
WO1994020137A1 (en) 1994-09-15
JP2010099091A (ja) 2010-05-06
DE69434383T2 (de) 2005-11-24
DK0688227T3 (da) 2005-06-27
DE69434383D1 (de) 2005-06-30
ES2263406T3 (es) 2011-06-06
EP1618888A1 (en) 2006-01-25
EP1588713B1 (en) 2010-12-22
DE122011100018I1 (de) 2011-11-17
JP2007075117A (ja) 2007-03-29
LU91313I2 (fr) 2007-04-23
PT1618888E (pt) 2011-04-08
ES2242955T4 (es) 2010-04-12
EP0688227A4 (en) 1996-05-29
DE69435331D1 (de) 2011-02-03
NL300309I1 (nl) 2008-02-01
ES2263405T3 (es) 2011-04-20
AU2007201006B2 (en) 2010-07-01
PT688227E (pt) 2005-10-31
DK1618888T3 (da) 2011-04-04
JP5306251B2 (ja) 2013-10-02
ES2263405T1 (es) 2006-12-16
DE122007000089I1 (de) 2008-03-27
JP5386392B2 (ja) 2014-01-15
ES2242955T3 (es) 2005-11-16
HK1082206A1 (en) 2006-06-02
FR11C0022I1 (enExample) 2011-05-08
JPH08507685A (ja) 1996-08-20

Similar Documents

Publication Publication Date Title
ATE492289T1 (de) Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
DE69535018D1 (de) Papillomavirus vakzine
ATE288489T1 (de) Vp-antigene des jc-virus
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties